Home Cart Sign in  
Chemical Structure| 920509-32-6 Chemical Structure| 920509-32-6

Structure of Resmetirom
CAS No.: 920509-32-6

Chemical Structure| 920509-32-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MGL-3196 is a selective thyroid hormone receptor β agonist with EC50s of 0.21 and 3.74 µM for TRβ and TRα respectively.

Synonyms: MGL-3196; VIA-3196

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Resmetirom

CAS No. :920509-32-6
Formula : C17H12Cl2N6O4
M.W : 435.22
SMILES Code : N#CC1=NN(C2=CC(Cl)=C(OC(C=C3C(C)C)=NNC3=O)C(Cl)=C2)C(NC1=O)=O
Synonyms :
MGL-3196; VIA-3196
MDL No. :MFCD26142653
InChI Key :FDBYIYFVSAHJLY-UHFFFAOYSA-N
Pubchem ID :15981237

Safety of Resmetirom

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 0.1 µM 16 hours Validate the effects of glucocorticoids and thyroid hormone on ACBP/DBI expression. Results showed that glucocorticoids induced ACBP/DBI release, while T3 downregulated ACBP/DBI mRNA levels. PMC11659162
HEK-1B1 cells 600 nM 24 hours To compare the induction of TH target genes by MGL-3196 and T3, finding stronger induction of KLF9 and PCK1 in TRβ-overexpressing cells. PMC9691000
HEK293 cells 10 nM–100 µM 24 hours To assess MGL-3196 action in HEK-1B1 and HEK-1B3 cells, finding OATP1B1 as the primary transporter for MGL-3196. PMC9691000
HEK-1B1 cells 6 µM 48 hours To measure the oxygen consumption rate, finding that MGL-3196 increases basal respiration, maximal respiration, ATP production, and proton leak, functionally mimicking T3. PMC9691000
NCTC 1469 cells 100 μM 48 hours To test the preventive effect of resmetirom on NASH cell model, results showed that resmetirom effectively eliminated lipid accumulation and decreased triglyceride (TG) levels. PMC10058113
HepG2 cells 100 μM 48 hours To test the preventive effect of resmetirom on NASH cell model, results showed that resmetirom effectively eliminated lipid accumulation and decreased triglyceride (TG) levels. PMC10058113
H4 human neuroglioma cells 5 µM 6 or 24 hours Evaluate the impact of 710 distinct agonists and antagonists of neurotransmitter and hormone receptors on ACBP/DBI expression. Results showed that glucocorticoids (e.g., hydrocortisone and dexamethasone) reduced ACBP/DBI expression, while thyroid hormone (T3) downregulated ACBP/DBI mRNA levels. PMC11659162
Huh7 cells 46.0 μM overnight To evaluate the effect of Resmetirom alone or in combination with ACCi on fatty acid oxidation. Res alone induced FAO 1.6-fold, and in combination with ACCi, the Emax of Res increased by 158%. PMC9426400

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Cushing’s syndrome model Oral 0.033 mg/ml 5 weeks Evaluate the effects of Resmetirom on metabolic symptoms of Cushing’s syndrome. Results showed that Resmetirom reduced ACBP/DBI mRNA levels in liver and adipose tissue and reversed corticosterone-induced metabolic abnormalities such as increased appetite, weight gain, adiposity, and insulin resistance. PMC11659162
Rats High-fat diet-induced dyslipidemic rat model Oral 1 mg/kg and 3 mg/kg Once daily for 1 week To evaluate the effect of Resmetirom alone or in combination with ACCi on liver TG and circulating TG. Res dose-dependently reduced liver TG (83% and 88%) and mitigated ACCi-induced hypertriglyceridemia. PMC9426400
C57BL/6J mice NASH Mice model Oral 3 mg/kg and 5 mg/kg Daily administration for 48 days To test the therapeutic effect of resmetirom on NASH Mice model, results showed that resmetirom significantly improved liver pathological features, reduced lipid accumulation and fibrosis, and inhibited the activation of STAT3 and NF-κB signaling pathways. PMC10058113
C57BL/6 mice High-fat diet-induced NAFLD model Oral administration in drinking water 9.35 mg/kg or 2.8 mg/kg 2 or 3 weeks To investigate the effect of TG68 on fatty liver accumulation and liver injury in mice fed a high-fat diet. Results showed that TG68 treatment led to a reduction in liver weight, hepatic steatosis, serum transaminases, and circulating triglycerides. PMC8657920

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04951219 Non-Alcoholic Fatty Liver Dise... More >>ase Less << PHASE3 RECRUITING 2025-04-26 Central Research Associates, B... More >>irmingham, Alabama, 35205, United States|Arizona Liver Health - Chandler, Chandler, Arizona, 85224, United States|East Valley Family Physicians, Chandler, Arizona, 85224, United States|The Institute For Liver Health - Glendale, Glendale, Arizona, 85306, United States|The Institute For Liver Health - Tucson, Tucson, Arizona, 85711, United States|Adobe Gastroenterology, Tucson, Arizona, 85712, United States|Arkansas Gastroenterology, North Little Rock, Arkansas, 72117, United States|Fresno Clinical Research Center, Fresno, California, 93720, United States|National Research Institute - Huntington Park, Huntington Park, California, 90255, United States|Ruane Clinical Research Group, Los Angeles, California, 90036, United States|Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States|National Research Institute - Los Angeles, Los Angeles, California, 90057, United States|Catalina Research Institute, Montclair, California, 91763, United States|National Research Institute - Panorama City, Panorama City, California, 91402, United States|San Fernando Valley Health Institute, West Hills, California, 91307, United States|South Denver Gastroenterology - Swedish Medical Center Office, Englewood, Colorado, 80113, United States|Excel Medical Clinical Trials, Boca Raton, Florida, 33434, United States|Covenant Research, Fort Myers, Florida, 33912, United States|Velocity Clinical Research, Hallandale Beach (MD Clinical), Hallandale Beach, Florida, 33009, United States|Floridian Clinical Research, Hialeah, Florida, 33016, United States|Nature Coast Clinical Research - Inverness, Inverness, Florida, 34452, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, 32216, United States|Florida Research Institute, Lakewood Ranch, Florida, 34211, United States|Miami Dade Medical Research Institute, Miami, Florida, 33176, United States|Orlando Research Center, Orlando, Florida, 32806, United States|Progressive Medical Research, Port Orange, Florida, 32127, United States|Covenant Research, Sarasota, Florida, 34240, United States|The Villages Research Center, The Villages, Florida, 32162, United States|Gastrointestinal Specialists of Georgia, Marietta, Georgia, 30060, United States|East-West Medical Research Institute, Honolulu, Hawaii, 96814, United States|Chicago Research Center, Chicago, Illinois, 60602, United States|Northwestern Memorial Physicians Group, Chicago, Illinois, 60611, United States|Iowa Diabetes Research, West Des Moines, Iowa, 50265, United States|Kansas Medical Clinic - Gastroenterology, Topeka, Kansas, 66606, United States|L-MARC Research Center, Louisville, Kentucky, 40213, United States|Digestive Health Center of Louisiana, Baton Rouge, Louisiana, 70809, United States|Tandem Clinical Research - New Orleans Area Site, Marrero, Louisiana, 70072, United States|Clinical Trials of America, West Monroe, Louisiana, 71291, United States|Gastrointestinal Associates & Endoscopy Center - Flowood, Flowood, Mississippi, 39232, United States|Southern Therapy and Advanced Research, Jackson, Mississippi, 39216, United States|Kansas City Research Institute, Kansas City, Missouri, 64131, United States|Henderson Research Center, Henderson, Nevada, 89052, United States|Clarity Clinical Research, East Syracuse, New York, 13057, United States|Mount Sinai Health System, New York, New York, 10029, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Cumberland Research Associates, Fayetteville, North Carolina, 28304, United States|Diabetes and Endocrinology Consultants, Morehead City, North Carolina, 28557, United States|Platinum - Sterling Research Group - Springdale, Cincinnati, Ohio, 45246, United States|Aventiv Research Columbus, Columbus, Ohio, 43213, United States|Awasty Research Network, Marion, Ohio, 43302, United States|Premier Medical Group - Clarksville - Dunlop Lane, Clarksville, Tennessee, 37040, United States|Gastro One - Germantown Office - Wolf Park Drive, Germantown, Tennessee, 38138, United States|Pinnacle Clinical Research - Austin, Austin, Texas, 78746, United States|The Liver Institute At Methodist Dallas, Dallas, Texas, 75203, United States|Dallas Research Center, Dallas, Texas, 75234, United States|Liver Center of Texas, Dallas, Texas, 75234, United States|South Texas Research Institute, Edinburg, Texas, 78539, United States|Texas Digestive Disease Consultants, Fort Worth, Texas, 76104, United States|Liver Associates of Texas, Houston, Texas, 77030, United States|Doctor's Hospital at Renaissance, McAllen, Texas, 78504, United States|Plano Research Center, Plano, Texas, 75093, United States|Texas Liver Institute/American Research Corporation, San Antonio, Texas, 78215, United States|Pinnacle Clinical Research - San Antonio, San Antonio, Texas, 78229, United States|San Antonio Research Center, San Antonio, Texas, 78229, United States|Texas Digestive Disease Consultants - San Marcos, San Marcos, Texas, 78666, United States|Impact Research Institute, Waco, Texas, 76710, United States|Texas Digestive Disease Consultants - Bay Area Houston Endoscopy Center, Webster, Texas, 77598, United States|Wasatch Peak Family Practice, Layton, Utah, 84041, United States|Salt Lake City Research Center, Murray, Utah, 84123, United States|Bon Secours Liver Institute of Richmond, Richmond, Virginia, 23226, United States|National Clinical Research - Richmond, Richmond, Virginia, 23294, United States|Virginia Commonwealth University School of Medicine, Richmond, Virginia, 23298, United States|Liver Institute Northwest, Seattle, Washington, 98105, United States|Fundacion de Investigacion de Diego, San Juan, Puerto Rico Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.49mL

2.30mL

1.15mL

22.98mL

4.60mL

2.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories